Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IBD0333
- Development stage
- Phase 2
- Lead developer
- SUNHO BioPharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IBD0333 is a bispecific monoclonal antibody that targets both the cell surface antigen CD24 (Cluster of Differentiation 24) and the costimulatory receptor 4-1BB (also known as CD137 or TNFRSF9) (Tumor necrosis factor receptor superfamily member 9). By binding to CD24, which is overexpressed on certain tumor cells, and simultaneously activating 4-1BB on immune cells such as CD8+ T cells, IBD0333 aims to stimulate an antitumor immune response. This dual targeting approach has potential immunostimulating and antineoplastic (anticancer) activities. IBD0333 is being developed primarily for the treatment of advanced solid tumors and is currently in early-phase clinical trials.
- Other names
- anti-cd24/anti-4-1bb bispecific monoclonal antibody
02
Targets
CD24 (Cluster of Differentiation 24)TNFRSF9 (CD137 extracellular domain)
Beyond the preview
Go deeper on IBD0333.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IBD0333.